Hantavirus Cardiopulmonary Syndrome Follow-up
- Author: Juliet D Caldwell, MD; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD more...
Further Inpatient Care
High positive end-expiratory pressure (PEEP) and high fraction of inspired oxygen (FIO2) are often useful.
Pressure-controlled ventilation and inverse inspiration/expiration (I/E) ratio ventilation are beneficial in select cases.
Careful hemodynamic management optimizes survival.
Maintain mean arterial pressure greater than 70 mm Hg through a measured use of fluids and pressors.
Pulmonary artery catheterization may be used to avoid fluid overload: Maintain PAOP at 12 mm Hg or below.
Use vasoactive infusions early and liberally. (See Medication.)
Extracorporeal membrane oxygenation (ECMO)
The University of New Mexico Hospital (located in southeast corner of the four corners region) performed extensive research from 1994-2006 to determine the usefulness of ECMO rescue therapy in Hantavirus cardiopulmonary syndrome (HCPS). Given its investigational status, only patients with a projected 100% mortality rate and with clinical and laboratory evidence of HCPS were eligible to receive ECMO. Qualified patients had to demonstrate a cardiac index of less than 2 L/min, a PaO2/FIO2 ratio of less than 60, as well as refractory shock not responsive to standard medical therapy. Remarkably, among the 38 patients who qualified, approximately two thirds survived to recover completely. The cardiovascular collapse of HCPS is profound but uniquely brief; rescue bridging with ECMO yields complete recovery in many previously believed to be irrecoverable.
ECMO therapy appears to improve survival in a select group of patients with severe disease; an early effort should be made to transfer patients suspected of having HCPS to facilities capable of ECMO.[37, 27, 47] It is possible that earlier institution of ECMO could yield even greater survival benefits.
Patients with prolonged cardiac arrest or prolonged cerebral hypoxia are not candidates for ECMO.
Most cases of HCPS occur in rural communities where facilities equipped for aggressive intensive care are often lacking. Given the precipitous nature of this disease, consider the following:
Transport early: A patient who subsequently does not require aggressive therapies at a tertiary care center is preferable to a patient who deteriorates suddenly and dies en route.
Transport quickly: Use the fastest and best-equipped transport, whether it be fixed-wing aircraft, rotor, or ground transportation, depending on proximity.
Transport to the highest level of care center possible: Again, anticipate the possible need for intensive care and possibly ECMO.
Prepare for clinical decline en route: Anticipate the need for fluids and vasopressors.
The best way to prevent HCPS is to avoid all exposure to rodents, especially deer mice, and their excreta.
Tips on rodent-proofing homes indoors and outdoor may be found at All About Hantaviruses - Prevention Indoors and Outdoors.
Never sweep or vacuum rodent-infested areas as this further aerosolizes the virus. Instead, wet the area thoroughly with disinfectant before cleaning, wearing rubber gloves. Other tips on cleaning infested areas may be viewed at All About Hantaviruses - Clean Up Infested Areas, Using Safety Precautions.
Homes with heavy infestations or homes of patients with confirmed HCPS require special precautions for cleaning. Contact the local health department for guidance. CDC recommendations may be found at All About Hantaviruses - Special Precautions for Homes of Persons with Confirmed Hantavirus Infection or Buildings with Heavy Rodent Infestations.
Persons who frequently handle or are exposed to rodents (eg, mammalogists, pest-control workers) in affected areas are probably at higher risk for Hantavirus infection than the general public because of their frequency of exposure. Therefore, enhanced precautions are warranted to protect them against Hantavirus infection. These precautions may be found at All About Hantaviruses - Precautions for Workers in Affected Areas Who are Regularly Exposed to Rodents.
Presently, no vaccines are approved for use against Hantaviruses in the United States. However, researchers are exploring the efficacy and safety of killed-virus vaccines as well as DNA vector derived antigen vaccines with some promising results in human and animal models.[26, 48, 49, 50, 51]
China and Korea offer a killed-virus vaccine for Hantaan virus and Seoul virus, but cost precludes widespread usage in many affected areas.
Although indirect evidence exists to suggest a role for passive immunization, no regimen has yet been developed. Interestingly, patients who present with high titers of neutralizing antibodies to Sin Nombre virus (SNV) tend to exhibit milder disease than those who present with low titers of neutralizing antibodies. Patients with low titers more often died or required extracorporeal membrane oxygen salvage therapy. Additionally, administration of antisera harvested from those who survived HCPS appears to mitigate the severity of disease in actively infected individuals. Given these findings, further study is warranted.
Potential acute complications of Hantavirus cardiopulmonary syndrome (HCPS) include death, cardiovascular collapse, respiratory failure, anoxic brain injury, renal failure, pulseless electrical activity (PEA), ventricular tachycardia, and ventricular fibrillation.
ECMO has its own set of significant and not infrequent complications, including massive hemorrhage, sepsis, renal failure, and limb ischemia. ECMO remains a rescue therapy for patients who are deteriorating despite maximal conventional medical therapy.
HCPS currently carries a case-mortality rate of 35-40%.[47, 27] Preadolescents seem to experience a milder form of the disease and have had no reported deaths in the United States.
Experiences with HCPS at the University of New Mexico Hospital have identified several factors that resulted in a 100% mortality rate in several patients who do not receive ECMO. These include the following:
Cardiac index less than 2.5 L/min/m 2
Ventricular tachycardia, ventricular fibrillation, or PEA
Hypotension despite adequate fluid resuscitation and vasoactive pressors
Educate patients and their families regarding the following:
Prodromal symptoms of HCPS
Risk of transmission by contact with rodents or rodent excreta
Techniques to safely clean-up infested areas
Rodent control measures (See Deterrence/Prevention.)
Sheedy JA, Froeb HF, Batson HA, et al. The clinical course of epidemic hemorrhagic fever. Am J Med. 1954 May. 16(5):619-28. [Medline].
Lee HW, Baek LJ, Johnson KM. Isolation of Hantaan virus, the etiologic agent of Korean hemorrhagic fever, from wild urban rats. J Infect Dis. 1982 Nov. 146(5):638-44. [Medline].
Brummer-Korvenkontio M, Vaheri A, Hovi T, et al. Nephropathia epidemica: detection of antigen in bank voles and serologic diagnosis of human infection. J Infect Dis. 1980 Feb. 141(2):131-4. [Medline].
Avsic-Zupanc T, Xiao SY, Stojanovic R, Gligic A, van der Groen G, LeDuc JW. Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia. J Med Virol. 1992 Oct. 38(2):132-7. [Medline].
Tsai TF, Bauer SP, Sasso DR, et al. Serological and virological evidence of a Hantaan virus-related enzootic in the United States. J Infect Dis. 1985 Jul. 152(1):126-36. [Medline].
Glass GE, Watson AJ, LeDuc JW, Childs JE. Domestic cases of hemorrhagic fever with renal syndrome in the United States. Nephron. 1994. 68(1):48-51. [Medline].
Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention. Infectious diseases update: outbreak, hantavirus infection--southwestern United States, 1993. JAMA. 1993 Jul 7. 270(1):25. [Medline].
Centers for Disease Control and Prevention. All About Hantavirus Web site. Available at http://www.cdc.gov/ncidod/diseases/hanta/hps.
Klein SL, Calisher CH. Emergence and persistence of hantaviruses. Curr Top Microbiol Immunol. 2007. 315:217-52. [Medline].
Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-southern oscillation. J Infect Dis. 2000 May. 181(5):1569-73. [Medline].
Trencseni T, Keleti B. Clinical aspects and epidemiology of haemorrhagic fever with renal syndrome. Budapest. Akademai Kiado. 1971.
Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis. 2007 Jun 1. 195(11):1563-71. [Medline].
Terajima M, Hendershot JD 3rd, Kariwa H, et al. High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis. 1999 Dec. 180(6):2030-4. [Medline].
Xiao R, Yang S, Koster F, Ye C, Stidley C, Hjelle B. Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis. 2006 Nov 15. 194(10):1403-9. [Medline].
Mertz GJ, Hjelle BL, Bryan RT. Hantavirus infection. Adv Intern Med. 1997. 42:369-421. [Medline].
Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 2004. 17(4):481-97. [Medline].
Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 1999. 50:531-45. [Medline].
Li Y, Wang W, Wang JP, Pan L, Zhang Y, Yu HT. Elevated vascular endothelial growth factor levels induce hyperpermeability of endothelial cells in hantavirus infection. J Int Med Res. 2012. 40(5):1812-21. [Medline].
Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol. 1995 Jan. 26(1):110-20. [Medline].
Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med. 1996 Feb. 24(2):252-8. [Medline].
Entwisle G, Hale E. Hemodynamic alterations in hemorrhagic fever. Circulation. 1957 Mar. 15(3):414-25. [Medline].
Centers for Disease Control and Prevention. Outbreak of Hantavirus Infection in Yosemite National Park. Available at http://www.cdc.gov/hantavirus/outbreaks/yosemite-national-park-2012.html. Accessed: April 17, 2013.
Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. [Epidemic outbreak of Hantavirus pulmonary syndrome in Argentina. Molecular evidence of person to person transmission of Andes virus]. Medicina (B Aires). 1998. 58 Suppl 1:27-36. [Medline].
Young JC, Hansen GR, Graves TK, et al. The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg. 2000 Jun. 62(6):714-7. [Medline].
Johnson AM, Bowen MD, Ksiazek TG, et al. Laguna Negra virus associated with HPS in western Paraguay and Bolivia. Virology. 1997 Nov 10. 238(1):115-27. [Medline].
Chang B, Crowley M, Campen M, Koster F. Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med. 2007 Apr. 28(2):193-200. [Medline].
Centers for Disease Control and Prevention. Reported Cases of HPS. Available at http://www.cdc.gov/hantavirus/surveillance/index.html. Accessed: April 17, 2013.
MMWR Hantavirus Pulmonary Syndrome in Five Pediatric Patients --- Four States, 2009. December 25th 2009. 58 (50):1409-1412.
Castillo C, Naranjo J, Sepulveda A, Ossa G, Levy H. Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults. Chest. 2001 Aug. 120(2):548-54. [Medline].
Koster F, Foucar K, Hjelle B, Scott A, Chong YY, Larson R. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. Am J Clin Pathol. 2001 Nov. 116(5):665-72. [Medline].
Jenison S, Hjelle B, Simpson S, Hallin G, Feddersen R, Koster F. Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Semin Respir Infect. 1995 Dec. 10(4):259-269. [Medline].
Hjelle B. Hantavirus Cardiopulmonary Syndrome. UpToDate. 2008.
Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med. 1994 Apr 7. 330(14):949-55. [Medline].
Ketai LH, Williamson MR, Telepak RJ, et al. Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology. 1994 Jun. 191(3):665-8. [Medline].
Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg. 2008 Mar. 135(3):579-84. [Medline].
Dull SM, Brillman JC, Simpson SQ, Sklar DP. Hantavirus pulmonary syndrome: recognition and emergency department management. Ann Emerg Med. 1994 Sep. 24(3):530-6. [Medline].
Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med. 1994 Jun. 149(6):1710-3. [Medline].
Crowley MR, Katz RW, Kessler R, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med. 1998 Feb. 26(2):409-14. [Medline].
Hjelle B, Jenison S, Mertz G, et al. Emergency of hantaviral disease in southwestern United States. West J Med. 1994. 161:467.
Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991 Dec. 164(6):1119-27. [Medline].
Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther. 1999. 4(4):211-9. [Medline].
Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004 Nov 1. 39(9):1307-13. [Medline].
Vial PA, Valdivieso F, Ferres M, Riquelme R, Rioseco ML, Calvo M, et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013 Oct. 57(7):943-51. [Medline]. [Full Text].
Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis. 2000 Jul. 182(1):43-8. [Medline].
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008 Apr. 78(1):162-9. [Medline].
Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol. 2003 Sep. 77(18):9894-905. [Medline].
Hooper JW, Custer DM, Smith J, Wahl-Jensen V. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology. 2006 Mar 30. 347(1):208-16. [Medline].
Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol. 1990 Jul. 64(7):3162-70. [Medline].
Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg. 1992 Oct. 47(4):397-404. [Medline].
Vial PA, Valdivieso F, Calvo M, Rioseco ML, Riquelme R, Araneda A, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome by ANDV. Antivir Ther. 2014 Oct 15. [Medline].
Howard MJ, Doyle TJ, Koster FT, et al. Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis. 1999 Dec. 29(6):1538-44. [Medline].
CDC. Hantavirus pulmonary syndrome in five pediatric patients - four states, 2009. MMWR Morb Mortal Wkly Rep. 2009 Dec 25. 58(50):1409-12. [Medline].
Pergam SA, Schmidt DW, Nofchissey RA, et al. Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am J Trop Med Hyg. 2009 Feb. 80(2):279-85. [Medline].